US Stock MarketDetailed Quotes
XOMA XOMA Corp
- 24.080
- -1.710-6.63%
Close Jun 3 16:00 ET
- 24.080
- 0.0000.00%
Post 16:13 ET
280.26MMarket Cap-6142P/E (TTM)
26.000High24.050Low32.34KVolume26.000Open25.790Pre Close788.28KTurnover0.41%Turnover RatioLossP/E (Static)11.64MShares27.00052wk High3.41P/B191.73MFloat Cap13.48052wk Low0.54Dividend TTM7.96MShs Float5324.997Historical High2.24%Div YieldTTM7.56%Amplitude3.960Historical Low24.376Avg Price1Lot Size
XOMA Corp Stock Forum
Sign in to post a comment
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Biotech Stock News 01/12 @ Open 🛎️📰
$Dyne Therapeutics(DYN.US$ 4% Closing of public offering
$Geron(GERN.US$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US$ 2% Capital increase
$XOMA Corp(XOMA.US$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US$ 1% Topline results @ conf. call
$CytomX(CTMX.US$ 0% Present @ B. Riley Sec. Conf. '24
$Dyne Therapeutics(DYN.US$ 4% Closing of public offering
$Geron(GERN.US$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US$ 2% Capital increase
$XOMA Corp(XOMA.US$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US$ 1% Topline results @ conf. call
$CytomX(CTMX.US$ 0% Present @ B. Riley Sec. Conf. '24
2
The FDA's acceptance of the NDA is a positive step for XOMA, triggering a milestone payment and bringing the drug closer to potential approval and commercialization. This could lead to future milestone and royalty payments for XOMA, depending on arimoclomol's commercial success.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?